Denali Therapeutics (DNLI) Payables (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Payables data on file, last reported at $40.4 million in Q1 2026.

• On a quarterly basis, Payables rose 377.42% year-over-year to $40.4 million in Q1 2026; TTM through Mar 2026 was $40.4 million, a 377.42% increase from a year earlier, with the FY2025 full-year figure at $505000.0, down 95.47% from the prior year.
• Payables for Q1 2026 stood at $40.4 million, up from $505000.0 in the prior quarter.
• Over the last five years, Payables for DNLI reached as high as $40.4 million in Q1 2026 and fell as low as $505000.0 in Q4 2025.
• Historically, Payables has averaged $10.0 million across 5 years, with a median of $8.5 million in 2023.
• Across the five-year window, Payables tumbled 95.47% in 2025 and surged 377.42% in 2026, its largest moves.
• Year by year, Payables stood at $2.8 million in 2022, then jumped by 239.89% to $9.5 million in 2023, then gained by 17.44% to $11.1 million in 2024, then tumbled by 95.47% to $505000.0 in 2025, then surged by 7896.04% to $40.4 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $40.4 million in Q1 2026, $505000.0 in Q4 2025, and $6.7 million in Q3 2025.